---
title: Efficacy of a Dietary Supplement in Infants
nct_id: NCT07341477
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Société des Produits Nestlé (SPN)
study_type: INTERVENTIONAL
primary_condition: Healthy Infants
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07341477.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07341477"
ct_last_update_post_date: 2026-04-24
last_seen_at: "2026-05-12T06:27:51.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy of a Dietary Supplement in Infants

**Official Title:** Microbiome and Health-related Effects of a Dietary Supplement in Infants: a Double-blind, Randomized, Placebo-controlled Nutritional Study.

**NCT ID:** [NCT07341477](https://clinicaltrials.gov/study/NCT07341477)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 172
- **Lead Sponsor:** Société des Produits Nestlé (SPN)
- **Conditions:** Healthy Infants
- **Start Date:** 2026-06
- **Completion Date:** 2027-12
- **CT.gov Last Update:** 2026-04-24

## Brief Summary

This is a double-blind, randomized, placebo-controlled nutritional study of healthy term infants. The primary objective of the trial is to demonstrate a favorable change in fecal microbiome composition in infants receiving a dietary supplement compared to infants receiving a placebo supplement.

## Detailed Description

This is a double-blind, randomized, placebo-controlled nutritional study of healthy term infants, consisting of 2 randomized parallel arms: experimental group (EG) receiving a dietary supplement and a control group (CG) receiving a placebo supplement.

The population under investigation is healthy infants aged 5 months +/- 1 week at the time of clinic visit 1.

The planned sample size for this study is 172 infants (86 per study group). Each investigational product (EG and CG) will be provided in powder form and packaged in single dose stick packs. The powder will be dissolved in lukewarm formula or body temperature breastmilk and fed orally to the infants using a provided infant feeding beaker.

The primary objective of the trial is to demonstrate a favorable change in fecal microbiome composition in infants receiving a dietary supplement compared to infants receiving a placebo supplement from enrolment until 5 months of intervention.

In addition, fecal metabolic biomarkers, gastrointestinal (GI) related outcomes, blood markers of immune health, fecal markers of gut and immune health, bone quality, other anthropometric measurements, dietary pattern and infant illness and infection outcomes will be assessed/measured.

## Eligibility

- **Minimum age:** 19 Weeks
- **Maximum age:** 21 Weeks
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Written informed consent has been obtained from at least one parent (or legally acceptable representative \[LAR\])
2. Parent(s) / LAR(s) must be able to provide evidence of parental authority and identity
3. Parent(s) / LAR(s) must understand the informed consent form and other study documents
4. Parent(s) / LAR(s) are willing and able to comply with scheduled visits and the requirements of the study protocol including infant blood collection
5. Parent(s) / LAR(s) can be contacted directly by telephone throughout the study
6. Parent(s) / LAR(s) must be able to temporarily store stool samples in a household freezer
7. Parent(s) / LAR(s) of formula-fed infants (either exclusively or mixed-fed) must have previously and independently decided to use formula and their infant must be consuming and tolerating a standard cow's milk infant formula not containing probiotics at the time of enrollment
8. Infant must be healthy based on medical history and physical examination
9. Infant full-term gestational birth (born 37 weeks, 0 days through 41 weeks, 6 days)
10. Infant age 5 months ± 1 week (date of birth = day 0) at time of clinic visit 1
11. Infant birth weight is appropriate for gestational age (i.e., ≥ 2500 and ≤ 4500 grams)

Exclusion Criteria:

1. Infants with conditions requiring specific infant feeding regimens other than those specified in the protocol
2. Infants receiving solid foods or liquids other than breastmilk or infant formula within 4 weeks prior to enrollment
3. Infants who have a medical condition or medical history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:

   1. Evidence of major congenital malformations (e.g., cleft palate, extremity malformation)
   2. Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis)
   3. Immunocompromised infants and those who have a central venous catheter
   4. History of admission to the Neonatal Intensive Care Unit, except for admission for jaundice phototherapy.
   5. Known or suspected allergy to milk (including lactose) or soy
   6. Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgement of the investigator, would make the infant inappropriate for entry into the study.
4. Infants who are currently receiving or who have received any probiotic supplements or any infant formula containing probiotics prior to enrollment
5. Infants who are currently receiving or who have previously received any of the following medication(s) or supplement(s) which are known or suspected to affect fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes), stool characteristics (e.g., glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose), growth (e.g. insulin or growth hormone), microbiome-related endpoints (e.g., prebiotic supplements, antibiotic usage within the past 4 weeks \[not including topical or ophthalmic applications\]), or gastric acid secretion.
6. Infants whose parent(s) / LAR(s) have not reached the legal age of majority (18 years old)
7. Infants who are currently or who previously participated in another interventional clinical study
8. Parent(s) / LAR(s) with family or hierarchical relationships with the research team members
```

## Arms

- **Experimental Group (EG)** (EXPERIMENTAL)
- **Control Group (CG)** (PLACEBO_COMPARATOR)

## Interventions

- **Experimental Group** (DIETARY_SUPPLEMENT) — Dietary supplement in powder form
- **Control Group (CG)** (OTHER) — Placebo dietary supplement in powder form

## Primary Outcomes

- **Probiotic abundance** _(time frame: At 5 months (V4) of intervention)_ — Fecal probiotic abundance

## Secondary Outcomes

- **Fecal metabolic biomarker** _(time frame: At baseline (V1), 3 months (V3), and 5 months (V4) of intervention.)_
- **Growth parameter: Weight** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3), and 5 months (V4) of intervention.)_
- **Growth parameter: Length** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3) and 5 months (V4) of intervention.)_
- **Growth parameter: Head circumference** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3) and 5 months (V4) of intervention.)_
- **GI-related Behavior: Infant Gastrointestinal Symptom Questionnaire (IGSQ)** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3) and 5 months (V4) of intervention.)_
- **GI-related behavior: Stool frequency** _(time frame: 1-day retrospective (V1) and 3-day prospective (V2, V3 and V4) of intervention)_
- **GI-related behavior: Stool consistency** _(time frame: 1-day retrospective (V1) and 3-day prospective (V2, V3 and V4) of intervention)_
- **GI-related behavior: Crying and sleeping** _(time frame: 1-day retrospective (V1) and 3-day prospective (V2, V3 and V4) of intervention)_
- **Fecal microbiota** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3), and 5 months (V4) of intervention.)_
- **Bone quality** _(time frame: At baseline (V1), 3 months (V3), and 5 months (V4) of intervention.)_
- **Dietary intake: Food record** _(time frame: 3 consecutive days prior to study visit 3 (age 8 months) and visit 4 (age 10 months))_
- **Dietary intake: Complementary foods** _(time frame: Questionnaire to be completed prospectively starting at age 6 months)_
- **Dietary intake: Formula Composition** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3), and 5 months (V4) of intervention.)_
- **Fecal markers of gut and immune health: Formula-fed infants only** _(time frame: At 1 month (V2), 3 months (V3), and 5 months (V4) of intervention in exclusively formula-fed infants only.)_
- **Fecal markers of gut and immune health: All infants** _(time frame: At baseline (V1), 1 month (V2), 3 months (V3), and 5 months (V4) of intervention in all infants.)_
- **Blood biomarkers** _(time frame: At baseline (V1), 3 months (V3), and 5 months (V4) of intervention.)_
- **Neurodevelopment: National Institute of Health (NIH) Baby Toolbox** _(time frame: At 5 months (V4) of intervention)_
- **Neurodevelopment: Heart rate variability** _(time frame: Assessed for 24 hours at home after baseline (V1), 3 months (V3), and 5 months (V4) of intervention.)_

## Recent Field Changes (last 30 days)

- `outcomes.secondary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07341477.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07341477*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*